KRAS and plasma cell myeloma: Promising options include monoclonal antibodies targeting myeloma directly or, alternatively, activating immune cells such as activated natural killer cells and CAR-T cells.15 Additionally, some patients may benefit from adding targeted therapy directed at N-RAS, K-RAS or BRAFF according to their mutational profile.16